Genzyme Corp. leases 136,000 s/f at 9/90 Corp. Center from National Dev. and UBS

According to National Development and UBS, Genzyme Corp. has leased a total of 136,000 rentable s/f at 9/90 Corporate Center. Previously occupying 26,000 s/f at 200 Crossing Blvrd., Genzyme extended and expanded its occupancy in the building to 80,000 s/f and also leased the entire 55,000 s/f building located at 200 Staples Dr. Rob Walles and Chris Tosti of CB Richard Ellis represented Genzyme and Joe Fallon and Sue Donovan of FHO Partners represented National Development and UBS in this transaction. "We are thrilled to have Genzyme expand its commitment to 9/90 Corporate Center," said Jack O'Neil, managing partner at National Development. 9/90 Corporate Center is a 147-acre, eight-building office park at the intersection of the Mass. Tpke. (I-90) and Rte. 9. The site is approximately 11 miles west of Rte. 128 (I-95) and 4 miles east of I-495. The park has many amenities including an on-site café, a 125-room Marriott Residence Inn, walking trails, restaurants and shopping within one-half mile, and on-site commuter bus service to and from the MBTA commuter rail station. Other occupants at the park include Staples, Inc. (world headquarters), Computer Associates International (regional headquarters), Cumberland Farms/Gulf (corporate headquarters), GTC Biotherapeutics, Avery Dennison and GlassHouse Technologies, among others. Genzyme is one of the world's leading biotechnology companies, making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe. National Development is one of the area's largest real estate firms and owns a significant portfolio of properties in eastern Massachusetts. The Newton-based firm develops, acquires and manages buildings throughout the region. Chris Tosti